Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Common Equity came in at $13.0 million in Q1 2026, up 137.04% YoY from $5.5 million in Q1 2025, and down 4.95% on a QoQ basis from $13.7 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Common Equity data on file, last reported at $13.0 million in Q1 2026.
- Quarterly Common Equity rose 137.04% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 137.04% YoY) and the FY2025 annual result came in at $13.7 million, up 146.22% from the prior year.
- Common Equity retreated to $13.0 million in Q1 2026, from $13.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $96.5 million in Q1 2022 to a low of -$35.1 million in Q1 2025.
- A 5-year average of $11.6 million and a median of $3.9 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 2336.49% — and 2024, when it plunged 832.81%.
- Tracing XERS's Common Equity over 5 years: stood at $45.2 million in 2022, then tumbled by 115.01% to -$6.8 million in 2023, then slumped by 336.67% to -$29.6 million in 2024, then surged by 146.22% to $13.7 million in 2025, then fell by 4.95% to $13.0 million in 2026.
- The last three Common Equity figures came in at $13.0 million (Q1 2026), $13.7 million (Q4 2025), and -$861000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | -9.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.73 Mn |
| Mar 31, 2026 | 13.01 Mn |
| Dec 31, 2025 | 13.69 Mn |
| Sep 30, 2025 | -861,000.00 |
| Jun 30, 2025 | -19.30 Mn |
| Mar 31, 2025 | -35.13 Mn |
| Dec 31, 2024 | -29.62 Mn |
| Sep 30, 2024 | -28.32 Mn |
| Jun 30, 2024 | -19.29 Mn |
| Mar 31, 2024 | -9.18 Mn |
| Dec 31, 2023 | -6.78 Mn |
| Sep 30, 2023 | 3.87 Mn |
| Jun 30, 2023 | 13.64 Mn |
| Mar 31, 2023 | 30.05 Mn |
| Dec 31, 2022 | 45.19 Mn |
| Sep 30, 2022 | 55.04 Mn |
| Jun 30, 2022 | 73.94 Mn |
| Mar 31, 2022 | 96.46 Mn |
| Dec 31, 2021 | 95.23 Mn |
| Sep 30, 2021 | -2.46 Mn |